Please click on the agreement button below to acknowledge that you are a healthcare provider.
A stable, consistent, and ready to use liquid spironolactone for adult patients who have difficulty swallowing.
Available in: 5mL unit dose cups | 118mL bottle | 473mL bottle
CaroSpir is the first and only FDA-approved oral suspension of spironolactone that provides a stable, ready to use, and consistent liquid treatment option for adult patients who have difficulty swallowing, or who cannot swallow tablets, and are suffering from heart failure, edema caused by heart failure and cirrhosis, and hypertension.
CaroSpir addresses the complexities and inconsistencies of crushing/compounding by providing patients with an FDA-approved oral liquid suspension of spironolactone. It eliminates the need for additional preparation by a pharmacist or patient and it does not have special storage requirements.
of older patients report missing doses of a tablet or capsule due to difficulties swallowing
Dysphagia is the medical term used to describe difficulty swallowing. It can include difficulty starting a swallow (oropharyngeal dysphagia), issues in the throat (pharyngeal dysphagia), and the sensation of food being stuck (esophageal dysphagia).
It’s important to optimize treatment plans for patients with dysphagia given these complications. Dysphagic patients who suffer from chronic heart failure, edema caused by heart or liver failure, and/or hypertension are often prescribed spironolactone that is crushed/
compounded from tablets into a liquid form.
more likely to die while in the hospital
more likely to need nursing home care
days longer in the hospital on average
higher hospital bills on average
Unfortunately, liquids derived from crushed/compounded tablets raise concerns about patient safety and efficacy, and they have come under increasing scrutiny from the FDA.
Patients who may need an oral liquid
“Crushing tablets or opening capsules should be avoided and liquid formulations should be used whenever possible”
Disparities in dosing potency are dependent upon many variables including the consistency of the preparation and are influenced by the compounding procedure, person compounding, and compounding vehicles.
Results demonstrated that CaroSpir, the first and only FDA approved spironolactone oral suspension, delivered a consistent potency of spironolactone dose to dose, compared to compounded preparations that routinely showed potency inconsistencies.
To receive more information about CaroSpir®, please fill out this form.
Fields marked with an * are required
Terms and Conditions
* Void where prohibited by law. CMP Pharma reserves the right to rescind, revoke or amend this program without notice. Offer not valid for patients eligible for benefits under Medicaid (including Medicaid managed care), Medicare, TRICARE, Veterans Affairs, FEHBP, or similar state or federal programs. Offer void where prohibited, taxed, or otherwise restricted. Offer good only in the U.S.A. No generic substitution with this offer.
CAROSPIR is an antagonist of aldosterone indicated for:
CAROSPIR is contraindicated for patients with the following conditions:
CAROSPIR may cause the following conditions.
The most common adverse reaction (incidence > 5%) with CAROSPIR treatment is the increased occurrence of gynecomastia in men.
Talk to your healthcare provider about other possible side effects with CAROSPIR. To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma, INC. at 1-844-321-1443 , or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
CAROSPIR oral suspension, 25 mg/5 mL, is not therapeutically equivalent to tablet forms of spironolactone. Follow dosing instructions for CAROSPIR. In patients requiring a dose greater than 100 mg, use another formulation of spironolactone. Doses of CAROSPIR suspension greater than 100 mg may result in spironolactone concentrations higher than expected.
Please see Prescribing Information for additional safety information.
CAROSPIR is an antagonist of aldosterone indicated for: the treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure; use as an add-on therapy for the treatment of hypertension, to lower blood pressure; the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restrictions.
CAROSPIR is contraindicated for patients with the following conditions: hyperkalemia; Addison’s disease; concomitant use of eplerenone.